Cargando…

Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease

In recent years, the global burden of obesity and diabetes has seen a parallel rise in other metabolic complications, such as non-alcoholic fatty liver disease (NAFLD). This condition, once thought to be a benign accumulation of hepatic fat, is now recognized as a serious and prevalent disorder that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ban, Linda A., Shackel, Nicholas A., McLennan, Susan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813235/
https://www.ncbi.nlm.nih.gov/pubmed/26985892
http://dx.doi.org/10.3390/ijms17030376
_version_ 1782424270756904960
author Ban, Linda A.
Shackel, Nicholas A.
McLennan, Susan V.
author_facet Ban, Linda A.
Shackel, Nicholas A.
McLennan, Susan V.
author_sort Ban, Linda A.
collection PubMed
description In recent years, the global burden of obesity and diabetes has seen a parallel rise in other metabolic complications, such as non-alcoholic fatty liver disease (NAFLD). This condition, once thought to be a benign accumulation of hepatic fat, is now recognized as a serious and prevalent disorder that is conducive to inflammation and fibrosis. Despite the rising incidence of NAFLD, there is currently no reliable method for its diagnosis or staging besides the highly invasive tissue biopsy. This limitation has resulted in the study of novel circulating markers as potential candidates, one of the most popular being extracellular vesicles (EVs). These submicron membrane-bound structures are secreted from stressed and activated cells, or are formed during apoptosis, and are known to be involved in intercellular communication. The cargo of EVs depends upon the parent cell and has been shown to be changed in disease, as is their abundance in the circulation. The role of EVs in immunity and epigenetic regulation is widely attested, and studies showing a correlation with disease severity have made these structures a favorable target for diagnostic as well as therapeutic purposes. This review will highlight the research that is available on EVs in the context of NAFLD, the current limitations, and projections for their future utility in a clinical setting.
format Online
Article
Text
id pubmed-4813235
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48132352016-04-06 Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease Ban, Linda A. Shackel, Nicholas A. McLennan, Susan V. Int J Mol Sci Review In recent years, the global burden of obesity and diabetes has seen a parallel rise in other metabolic complications, such as non-alcoholic fatty liver disease (NAFLD). This condition, once thought to be a benign accumulation of hepatic fat, is now recognized as a serious and prevalent disorder that is conducive to inflammation and fibrosis. Despite the rising incidence of NAFLD, there is currently no reliable method for its diagnosis or staging besides the highly invasive tissue biopsy. This limitation has resulted in the study of novel circulating markers as potential candidates, one of the most popular being extracellular vesicles (EVs). These submicron membrane-bound structures are secreted from stressed and activated cells, or are formed during apoptosis, and are known to be involved in intercellular communication. The cargo of EVs depends upon the parent cell and has been shown to be changed in disease, as is their abundance in the circulation. The role of EVs in immunity and epigenetic regulation is widely attested, and studies showing a correlation with disease severity have made these structures a favorable target for diagnostic as well as therapeutic purposes. This review will highlight the research that is available on EVs in the context of NAFLD, the current limitations, and projections for their future utility in a clinical setting. MDPI 2016-03-14 /pmc/articles/PMC4813235/ /pubmed/26985892 http://dx.doi.org/10.3390/ijms17030376 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ban, Linda A.
Shackel, Nicholas A.
McLennan, Susan V.
Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title_full Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title_fullStr Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title_full_unstemmed Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title_short Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease
title_sort extracellular vesicles: a new frontier in biomarker discovery for non-alcoholic fatty liver disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813235/
https://www.ncbi.nlm.nih.gov/pubmed/26985892
http://dx.doi.org/10.3390/ijms17030376
work_keys_str_mv AT banlindaa extracellularvesiclesanewfrontierinbiomarkerdiscoveryfornonalcoholicfattyliverdisease
AT shackelnicholasa extracellularvesiclesanewfrontierinbiomarkerdiscoveryfornonalcoholicfattyliverdisease
AT mclennansusanv extracellularvesiclesanewfrontierinbiomarkerdiscoveryfornonalcoholicfattyliverdisease